Recursion Pharmaceuticals (NasdaqGS:RXRX) reported positive early clinical data from its AI driven drug discovery programs. The company highlighted progress in oncology and rare disease candidates in ...

Recursion Pharmaceuticals (RXRX) has been drawing investor attention after recent trading shifts, with the stock closing at US$3.01 and showing mixed performance over the past week, month, and past ...

Recursion Pharmaceuticals (RXRX) has recently been on Zacks.com's list of the most searched stocks. Therefore, you might want to consider some of the key factors that could influence the stock's ...

Recursion Pharmaceuticals (RXRX) has been drawing attention after recent trading, with the stock closing at $4.67. Investors are weighing this price against the company’s clinical pipeline and ongoing ...

In recent days, Recursion Pharmaceuticals attracted heightened attention as traders responded to the stock’s very large short interest, alongside the announcement of a $12.5 million milestone payment ...